Id Pharma Co., Ltd.

Fudan University

Dna Vec Research Inc.

Japan, As Represented by the Director-general of National Institute of Infectious Disease

Tsugumine Shu

Makoto Inoue

Mamoru Hasegawa

Yasuji Ueda

Akihiro Iida

Hiroto Hara

Makoto Asakawa

Tetsuro Matano

Takahiro Hirata

Tsuyoshi Tokusumi

Yumiko Tokusumi

Xiao-Yong Fan

Kaio Kitazato

Zhi-Dong Hu

Hidekazu Kuma

Douglas B Lowrie

Fumino Tokito

In this invention, a non-infectious particle has been produced, comprising a pathogen antigen protein caused to be expressed on the surface of a virus particle having at least one species of paramyxovirus envelope protein missing from the particle. This particle has been found to hold within the particle a large amount of antigen protein compared to an infectious particle, and to be capable of eliciting a host immune response with extremely high efficiency. The non-infectious particle according to the present invention is useful as a vaccine against a pathogenic virus, or the like.

Infectious disease vaccine using non-infectious paramyxovirus particle

Provided in the present application are a recombinant sendai virus vector vaccine expressing immunodominant antigens of, and can be used as therapeutic and preventive antituberculosis vaccine.

Anti-vaccine using sendai virus as vector

F gene-deficient virus virions are successfully recovered by using an F gene-deficient Sendai virus genomic cDNA. Further, F gene-deficient infectious viral particles are successfully constructed by using F-expressing cells as helper cells. Also, F gene and HN gene-deficient virus virions are successfully recovered by using a virus genomic cDNA deficient in both F gene and HN gene. Further, F gene and HN gene-deficient infectious viral particles are successfully produced by using F- and HN-expressing cells as helper cells. A virus deficient in F gene and HN gene and having F protein is constructed by using F-expressing cells as helper cells. In addition, M gene-deficient infectious virus particles were produced using helper cells expressing M protein. From cells infected with M gene-deficient viruses, release of virus-like particles was inhibited. Further, a VSV-G pseudo type virus is successfully constructed by using VSV-G-expressing cells. Techniques for constructing these deficient viruses contribute to the development of vectors of Paramyxoviridae usable in gene therapy.

Envelope gene-deficient Paramyxovirus vector

Growing community of inventors

Ibaraki, Japan

Tsugumine Shu